<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04990479</url>
  </required_header>
  <id_info>
    <org_study_id>NOUS-PEV-01</org_study_id>
    <secondary_id>2019-004759-35</secondary_id>
    <nct_id>NCT04990479</nct_id>
  </id_info>
  <brief_title>Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma</brief_title>
  <official_title>An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of Nous-PEV, With Pembrolizumab, in Patients With Unresectable Stage III / IV Cutaneous Melanoma and With Stage IV NSCLC (PDL1≥ 50%)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nouscom SRL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nouscom SRL</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an international, multicenter, open-label, multiple cohort, First in Human, phase 1b&#xD;
      clinical study, designed to evaluate safety, tolerability, and immunogenicity, and to detect&#xD;
      any preliminary evidence of anti-tumor activity of a personalized vaccine (PEV) based on&#xD;
      GAd-PEV priming and MVA-PEV boosting, combined with SoC first-line immunotherapy using an&#xD;
      anti-PD-1 checkpoint inhibitor in patients with unresectable stage III/IV cutaneous melanoma&#xD;
      or with stage IV NSCLC (PDL1 ≥ 50%). The PEV vaccines will be prepared on an individual&#xD;
      basis, following a tumor biopsy performed at the time of screening and subsequent NGS&#xD;
      analysis, to identify patient-specific tumor mutations. Both neoantigen-encoding genetic&#xD;
      vaccines are administered intramuscularly using 1 prime with GAd-PEV and 3 boosts with&#xD;
      MVA-PEV in combination with the licensed programmed death receptor-1 (PD-1)-blocking antibody&#xD;
      pembrolizumab in adult patients in patients with unresectable stage III/IV cutaneous melanoma&#xD;
      (Cohort a) or with stage IV NSCLC (PDL1 ≥ 50%) (Cohort b).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overall Study Design:&#xD;
&#xD;
      • This is an open-label, non-randomized, dose-confirmation and cohort expansion phase 1b&#xD;
      first-in-human study, in which 28 patients, expandable up to 34 evaluable patients in case of&#xD;
      DLT.&#xD;
&#xD;
      Study IMPs:&#xD;
&#xD;
      Nous-PEV vaccine is composed of 2 sets of IMPs:&#xD;
&#xD;
        -  GAd-PEV&#xD;
&#xD;
        -  MVA-PEV&#xD;
&#xD;
      Treatment phases:&#xD;
&#xD;
      A) Induction phase with pembrolizumab (cycles 1, 2 and 3). B) Priming phase including 1&#xD;
      GAd-PEV administration with pembrolizumab (cycle 4).&#xD;
&#xD;
      C) Boosting phase including 3 boosting administrations of MVA-PEV with pembrolizumab (cycles&#xD;
      5, 6 and 7).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 7, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Treatment Cohorts of the study.&#xD;
Part 1:&#xD;
• Cohort 1a: 3 patients (expandable to 9) with unresectable stage III / IV Cutaneous Melanoma.&#xD;
Part 2&#xD;
Cohort 2a: 13 patients with unresectable stage III / IV Cutaneous Melanoma.&#xD;
Cohort 2b:12 patients with stage IV NSCLC (PDL1≥ 50%). In all cohorts, the treatment consists of four Nous-PEV vaccine administrations in combination with pembrolizumab as SoC.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability: incidence of treatment- emerging adverse events. AEs characterized by type, severity (graded by CTCAE v.5.0), Timing, seriousness and relationship to study treatments.</measure>
    <time_frame>Up to 110 weeks</time_frame>
    <description>Frequency, duration, and severity of adverse events (AEs) and serious adverse events (SAEs) using CTCAE v5.0 criteria.&#xD;
Changes in vital signs and clinical evaluations.&#xD;
Changes in clinical laboratory blood samples.&#xD;
Dose-limiting toxicity (DLT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RP2D confirmation 2. Clinical efficacy:</measure>
    <time_frame>Up to 110 weeks</time_frame>
    <description>RP2D confirmation based on safety and tolerability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy</measure>
    <time_frame>Up to 110 weeks</time_frame>
    <description>Clinical efficacy based on Overall response rate (ORR); Best overall response (BOR); Duration of response (DoR); Progression-free survival (PFS); Overall survival (OS), all as defined in tumor imaging, RECIST 1.1</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory outcome: immunogenicity</measure>
    <time_frame>Up to 110 weeks</time_frame>
    <description>PBMC-derived T-cell responses against vaccine FSPs, as measured by IFN-gamma ELISpot</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Melanoma (Skin)</condition>
  <condition>Non-Small-Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1a: 3 patients (expandable to 9) with unresectable stage III / IV Cutaneous Melanoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2a:13 patients with unresectable stage III / IV Cutaneous Melanoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2b: 12 patients with stage IV NSCLC (PDL1≥ 50%).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GAd-PEV</intervention_name>
    <description>Priming phase including 1 GAd-PEV administration with Standard of Care pembrolizumab (cycle 4).</description>
    <arm_group_label>Cohort 1a</arm_group_label>
    <arm_group_label>Cohort 2a</arm_group_label>
    <arm_group_label>Cohort 2b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-PEV</intervention_name>
    <description>Boosting phase including 3 boosting administrations of MVA-PEV with Standard of Care pembrolizumab (cycles 5, 6 and 7).</description>
    <arm_group_label>Cohort 1a</arm_group_label>
    <arm_group_label>Cohort 2a</arm_group_label>
    <arm_group_label>Cohort 2b</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Main Inclusion Criteria for Patients in Cohorts 1a and 2a:&#xD;
&#xD;
          1. Age ≥ 18 years.&#xD;
&#xD;
          2. Patients with histologically or cytologically confirmed unresectable stage III or&#xD;
             stage IV Cutaneous Melanoma, as per American Joint Committee on Cancer (AJCC) staging&#xD;
             system (8th edition).&#xD;
&#xD;
          3. Participation in this trial will be dependent upon supplying tumor tissue from newly&#xD;
             obtained specimen. Newly obtained biopsies of a tumor lesion, not previously&#xD;
             irradiated, must be provided in the form of excisional biopsies, resected tissue or&#xD;
             core needle biopsies.&#xD;
&#xD;
          4. Presence of at least 1 measurable lesion by computed tomography or magnetic resonance&#xD;
             imaging per RECIST v1.1 by the local site Investigator / radiologist assessment&#xD;
&#xD;
          5. Presence of at least one lesion amenable to repeated biopsy, ideally not the one being&#xD;
             used for measuring.&#xD;
&#xD;
          6. Willingness to undergo a minimum of two fresh lesion biopsies (pre-treatment and&#xD;
             on-treatment).&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.&#xD;
&#xD;
          8. Life expectancy of at least 12 months.&#xD;
&#xD;
          9. Adequate renal, hepatic, and hematologic functions.&#xD;
&#xD;
         10. A female patient is eligible to participate if she is not pregnant, not breastfeeding,&#xD;
             and woman of childbearing potential willing to use adequate contraception.&#xD;
&#xD;
         11. A male patient must agree to use adequate contraception.&#xD;
&#xD;
        Main Inclusion Criteria for Patients in Cohort 2b:&#xD;
&#xD;
          1. Age ≥ 18 years.&#xD;
&#xD;
          2. Histologically or cytologically confirmed stage IV squamous or non-squamous NSCLC&#xD;
             without EGFR or ALK /ROS1/RET genomic alteration.&#xD;
&#xD;
          3. Tumor expression with PD-L1 ≥50% tumor proportion score (TPS).&#xD;
&#xD;
          4. First-line treatment-naïve patients.&#xD;
&#xD;
          5. Participation in this trial will be dependent upon supplying tumor tissue from a newly&#xD;
             obtained specimen. Newly obtained biopsies of a tumor lesion, not previously&#xD;
             irradiated, must be provided in the form of excisional biopsies, resected tissue or&#xD;
             core needle biopsies.&#xD;
&#xD;
          6. Presence of at least 1 measurable lesion by computed tomography (CT) or magnetic&#xD;
             resonance imaging (MRI) per RECIST v1.1 as determined by the local site Investigator /&#xD;
             radiologist assessment.&#xD;
&#xD;
          7. Presence of at least one tumor lesion amenable to repeated biopsy, if possible,&#xD;
             ideally not the one being used for measuring.&#xD;
&#xD;
          8. Willingness to undergo a minimum of two fresh tumor biopsies (pre-treatment and&#xD;
             on-treatment).&#xD;
&#xD;
          9. ECOG performance status 0 to 1.&#xD;
&#xD;
         10. Life expectancy of at least 6 months.&#xD;
&#xD;
         11. Adequate renal, hepatic, and hematologic functions.&#xD;
&#xD;
         12. A female patient is eligible to participate if she is not pregnant, not breastfeeding,&#xD;
             and woman of childbearing potential willing to use adequate contraception.&#xD;
&#xD;
         13. A male patient must agree to use adequate contraception.&#xD;
&#xD;
        Main Exclusion Criteria for patients in all Cohorts:&#xD;
&#xD;
          1. Currently receiving treatment with another investigational medicinal product.&#xD;
&#xD;
          2. Prior therapy with immune checkpoint inhibitors. Patients must not have received any&#xD;
             investigational immunotherapy either.&#xD;
&#xD;
          3. Prior radiotherapy within 2 weeks of enrolment, or within 4 weeks of enrolment in the&#xD;
             case of radiation to central nervous system (CNS), which requires ≥ 4-week washout.&#xD;
&#xD;
          4. Prior allogenic tissue or solid organ transplant.&#xD;
&#xD;
          5. Active interstitial lung disease (ILD)/pneumonitis or a history of ILD/pneumonitis&#xD;
             requiring treatment with systemic steroids and/or whose pulse oxymetry is less than&#xD;
             92% &quot;on room air&quot;.&#xD;
&#xD;
          6. Major surgery within 12 weeks before enrolment.&#xD;
&#xD;
          7. Known additional malignancy that is progressing or requires active treatment, or&#xD;
             history of other malignancy within 2 years of study entry.&#xD;
&#xD;
          8. Immunosuppression including the continued use of systemic (at prednisone dose&#xD;
             equivalent of &gt; 10 mg) or topical steroids at or near the planned i.m. injection site&#xD;
             or the use of immunosuppressive agents for any concurrent condition in the 4 weeks&#xD;
             prior to first study treatment administration. Inhaled and eye drop-containing&#xD;
             corticosteroids are permitted.&#xD;
&#xD;
          9. Previous vaccination (either therapeutic and/or prophylactic) against cancer.&#xD;
&#xD;
         10. History of autoimmune disease in the last 5 years, including any active autoimmune&#xD;
             disease except vitiligo or childhood asthma.&#xD;
&#xD;
         11. Chronic or concurrent active infectious disease requiring systemic antibodies,&#xD;
             antifungal, or antiviral treatment.&#xD;
&#xD;
         12. Known Medical History of human immunodeficiency virus (HIV) infection or known Medical&#xD;
             History of acquired immunodeficiency syndrome (AIDS). HIV testing is not required&#xD;
             unless mandated by the local health authority.&#xD;
&#xD;
         13. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection that requires&#xD;
             treatment, or at risk for HBV reactivation.&#xD;
&#xD;
         14. Known CNS metastasis and/or carcinomatous meningitis.&#xD;
&#xD;
         15. Known cerebral edema.&#xD;
&#xD;
         16. Live vaccine received within 30 days before treatment initiation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Symeonides</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patricia Delaite, MD</last_name>
    <phone>(+39) 06 96036299</phone>
    <email>p.delaite@nouscom.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisa Scarselli, MD</last_name>
    <phone>(+39) 06 96036299</phone>
    <email>e.scarselli@nouscom.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Grand Hopital de Charleroi, Grand Rue 3, 6000 Charleroi (NOUS-PEV-01 site BE2)</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Hospital, Campus Gasthuisberg, Herestraat 49, 3000 Leuven (NOUS-PEV-01 site BE1)</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Bechter, MD</last_name>
      <email>Oliver.bechter@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Ingeborg Wauters</last_name>
      <email>ingeborg.wauters@uzleuven.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institut Catalá d'Oncologia ICO L'Hospitalet. Av Gran Via de L'Hospitalet 199-203. 08908 L'Hospitalet de Llobregat, Barcelona, Spain (NOUS-PEV-01 site ES4)</name>
      <address>
        <city>Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juan Martin-Liberal, MD</last_name>
      <email>jmartinliberal@iconcologia.net</email>
    </contact>
    <contact_backup>
      <last_name>Maria del Carmen Garcia Rodriguez</last_name>
      <email>mcgarciarodriguez@iconcologia.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>START Madrid - Centro Integral Oncológico Clara Campal, HM CIOCC Hospital Universitario HM Sanchinarro, 28050 Madrid. Spain (NOUS-PEV-01 site ES1)</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>START Madrid-FJD, Hospital Fundación Jiménez Diaz Avda. Reyes Católicos 2. 28040, Madrid, Spain (NOUS-PEV-01 site ES2)</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigación Sanitaria INCLIVA - Hospital Clínico Universitario de Valencia. Av. Blasco Ibáñez, 17 CP 46010 Valencia, Spain (NOUS-PEV-01 site ES3)</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrés Cervantes Ruipérez, MD</last_name>
      <email>andres.cervantes@uv.es</email>
    </contact>
    <contact_backup>
      <last_name>Inma Blasco</last_name>
      <email>iblasco@incliva.es</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cancer Research UK Edinburgh Centre. Western General Hospital, Edinburgh, EH4 2SP, UK (NOUS-PEV-01 site UK1)</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH4 2SP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/34452005/</url>
    <description>VENUS is a proprietary algorithm designed to enhance the predictive accuracy of personalized neoantigen selection, used in the NOUS-PEV-01 trial.</description>
  </link>
  <reference>
    <citation>Leoni G, D'Alise AM, Tucci FG, Micarelli E, Garzia I, De Lucia M, Langone F, Nocchi L, Cotugno G, Bartolomeo R, Romano G, Allocca S, Troise F, Nicosia A, Lahm A, Scarselli E. VENUS, a Novel Selection Approach to Improve the Accuracy of Neoantigens' Prediction. Vaccines (Basel). 2021 Aug 9;9(8). pii: 880. doi: 10.3390/vaccines9080880.</citation>
    <PMID>34452005</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 15, 2021</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

